Literature DB >> 533578

Pharmacokinetics of methylphenidate in hyperkinetic children.

B L Hungund, J M Perel, M J Hurwic, J Sverd, B G Winsberg.   

Abstract

1 Pharmacokinetic study has been carried out following oral administration of 10-20 mg of methylphenidate hydrochloride to four behaviorally disorders children. 2 It is indicated that the drug is metabolized to ritalinic acid with an apparent plasma half life of 2.5 h. 3 The variability in magnitude of plasma concentration seems to be due not to its metabolism to ritalinic acid but due to the variability in the apparent volume of distribution. 4 The brief half life of methylphenidate which parallels the short duration of action of methylphenidate in behaviorally disordered children may be explained in part by its low protein binding which results in high percentage of free drug being made available for metabolism to pharmacologically inactive metabolites.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533578      PMCID: PMC1429909          DOI: 10.1111/j.1365-2125.1979.tb01046.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  A STUDY OF STRUCTURE--ACTIVITY RELATIONSHIPS IN REGARD TO SPECIES DIFFERENCE IN THE PHENYLBUTAZONE SERIES.

Authors:  J M PEREL; M M SNELL; W CHEN; P G DAYTON
Journal:  Biochem Pharmacol       Date:  1964-09       Impact factor: 5.858

2.  [Ritalin, a new synthetic compound with specific analeptic components].

Authors:  R MEIER; F GROSS; J TRIPOD
Journal:  Klin Wochenschr       Date:  1954-05-15

3.  Pharmacokinetics of methylphenidate in the rat using single-ion monitoring GLC-mass spectrometry.

Authors:  J Gal; B J Hodshon; C Pintauro; B L Flamm; A K Cho
Journal:  J Pharm Sci       Date:  1977-06       Impact factor: 3.534

4.  Plasma concentration of amitriptyline and clinical response.

Authors:  R A Braithwaite; R Goulding; G Theano; J Bailey; A Coppen
Journal:  Lancet       Date:  1972-06-17       Impact factor: 79.321

5.  Plasma-nortriptyline levels in endogenous depression.

Authors:  P Kragh-Sørensen; M Asberg; C Eggert-Hansen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

6.  Plasma d-amphetamine absorption and elimination in hyperactive children.

Authors:  G L Brown; M H Ebert; R D Hunt
Journal:  Psychopharmacol Bull       Date:  1978-07

7.  Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Authors:  B H Dvorchik; E S Vessell
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

8.  A sensitive gas chromatographic method for the determination of methylphenidate (Ritalin) and its major metabolite alpha-phenyl-2-piperidine acetic acid (ritalinic acid) in human plasma using nitrogen-phosphorous detector.

Authors:  B L Hungund; M Hanna; B G Winsberg
Journal:  Commun Psychopharmacol       Date:  1978

9.  Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity.

Authors:  J Swanson; M Kinsbourne; W Roberts; K Zucker
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

10.  Clinical implications of imipramine plasma levels for depressive illness.

Authors:  A H Glassman; J M Perel; M Shostak; S J Kantor; J L Fleiss
Journal:  Arch Gen Psychiatry       Date:  1977-02
View more
  13 in total

Review 1.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  The persistence of stimulant effects in chronically treated children: further evidence of an inverse relationship between drug effects and placebo levels of response.

Authors:  C T Gualtieri; R E Hicks; J P Mayo; S R Schroeder
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  Cognitive effects of milacemide and methylphenidate in healthy young adults.

Authors:  J A Camp-Bruno; R L Herting
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

4.  Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.

Authors:  C P Collier; S J Soldin; J M Swanson; S M MacLeod; F Weinberg; J G Rochefort
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 5.  Drug treatment for hyperactive children. Therapeutic guidelines.

Authors:  J Elia
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

6.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

Review 8.  Risks and benefits of drugs used in the management of the hyperactive child.

Authors:  A M Fox; M J Rieder
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

9.  Methylphenidate oral dose plasma concentrations and behavioral response in children.

Authors:  B G Winsberg; S S Kupietz; J Sverg; B L Hungund; N L Young
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Methylphenidate increases selectivity of visual scanning in children referred for hyperactivity.

Authors:  M M Flintoff; R W Barron; J M Swanson; A Ledlow; M Kinsbourne
Journal:  J Abnorm Child Psychol       Date:  1982-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.